Revolution Medicines, Inc. (NASDAQ:RVMD) General Counsel Jeff Cislini Sells 1,500 Shares

Revolution Medicines, Inc. (NASDAQ:RVMD) General Counsel Jeff Cislini sold 1,500 shares of the stock in a transaction dated Wednesday, March 27th. The stock was sold at an average price of $30.99, for a total value of $46,485.00. Following the transaction, the general counsel now directly owns 54,374 shares in the company, valued at approximately $1,685,050.26. The transaction was disclosed in a filing with the SEC, which is available at this link.

Jeff Cislini also recently made the following trade(s):

• On Monday, March 18th, Jeff Cislini sold 1,252 shares of Revolution Medicines stock. The stock was sold at an average price of $31.58, for a total value of $39,538.16.
• On Monday, January 22nd, Jeff Cislini sold 1,500 shares of Revolution Medicines stock. The stock was sold at an average price of $27.00, for a total value of $40,500.00.

Revolution Medicines Stock Up 1.6 %

NASDAQ:RVMD traded up $0.51 during mid-day trading on Thursday, reaching $32.23. 997,438 shares of the stock were exchanged, compared to its average volume of 1,368,769. The company has a 50 day simple moving average of $29.90 and a 200-day simple moving average of $27.16. The stock has a market capitalization of $5.31 billion, a P/E ratio of -8.58 and a beta of 1.53. Revolution Medicines, Inc. has a 1 year low of $15.44 and a 1 year high of $35.60.

Revolution Medicines (NASDAQ:RVMD) last released its quarterly earnings results on Monday, February 26th. The company reported ($1.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.29). The firm had revenue of $0.74 million for the quarter, compared to analysts’ expectations of $1.20 million. Revolution Medicines had a negative return on equity of 38.39% and a negative net margin of 1,003.36%. The company’s quarterly revenue was down 95.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.63) EPS. As a group, research analysts predict that Revolution Medicines, Inc. will post -3.17 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in RVMD. MetLife Investment Management LLC grew its stake in Revolution Medicines by 58.5% during the 1st quarter. MetLife Investment Management LLC now owns 34,256 shares of the company’s stock worth $874,000 after buying an additional 12,643 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Revolution Medicines by 165.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 478,776 shares of the company’s stock valued at $12,214,000 after purchasing an additional 298,436 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of Revolution Medicines by 3.0% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 444,212 shares of the company’s stock valued at $11,332,000 after purchasing an additional 13,134 shares during the last quarter. Northern Trust Corp grew its stake in shares of Revolution Medicines by 12.3% in the 1st quarter. Northern Trust Corp now owns 629,849 shares of the company’s stock valued at $16,067,000 after purchasing an additional 68,794 shares during the last quarter. Finally, State Street Corp grew its stake in shares of Revolution Medicines by 3.2% in the 1st quarter. State Street Corp now owns 2,843,477 shares of the company’s stock valued at $72,537,000 after purchasing an additional 88,844 shares during the last quarter. Hedge funds and other institutional investors own 94.34% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. Piper Sandler initiated coverage on Revolution Medicines in a research note on Monday, March 11th. They set an “overweight” rating and a $43.00 target price on the stock. UBS Group initiated coverage on Revolution Medicines in a research report on Wednesday, December 20th. They issued a “buy” rating and a $40.00 price target on the stock. Raymond James increased their price target on Revolution Medicines from $30.00 to $36.00 and gave the company an “outperform” rating in a research report on Tuesday, January 16th. Bank of America raised Revolution Medicines from a “neutral” rating to a “buy” rating and increased their price target for the company from $31.00 to $34.00 in a research report on Friday, January 5th. Finally, Wedbush increased their price objective on Revolution Medicines from $41.00 to $42.00 and gave the company an “outperform” rating in a report on Tuesday, February 27th. Ten analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $38.80.

Revolution Medicines Company Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.